Form 4: Sanara MedTech COO Executes Tax Withholding Transaction

Chief Operating Officer Jacob A. Waldrop reported the withholding of 378 shares to satisfy tax obligations related to restricted stock vesting.

Summary

• Jacob A. Waldrop, Chief Operating Officer of Sanara MedTech Inc., reported a transaction involving the withholding of 378 shares of common stock.
• The transaction occurred on April 15, 2026, at a price of $20.01 per share.
• The withholding was executed to satisfy tax obligations associated with the vesting of 1,551 previously granted restricted stock units.
• Following this transaction, the reporting person maintains beneficial ownership of 24,377 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a mandatory tax withholding transaction rather than a market-driven trade.

Positives

• The transaction was a routine administrative action related to tax obligations rather than a discretionary sale of equity.
• The reporting person retains a significant equity stake of 24,377 shares, aligning interests with shareholders.

Negatives

• None identified; this is a standard tax-related withholding event.

Risks

• None identified; this filing pertains to routine executive compensation administration.

Future Outlook

Not applicable; this is a retrospective disclosure of an executive compensation event.

Industry Context

StockSavvy.ai notes that routine tax withholding filings are standard practice for executives receiving equity-based compensation and do not typically signal changes in management sentiment or company outlook.

Comparison to Industry Standards

• The transaction follows standard corporate governance practices for equity vesting and tax compliance observed across the medical technology sector.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-discretionary tax settlement.

Next Steps

• No further actions required by the reporting person regarding this specific transaction.

Key Dates

Keywords

Sanara MedTech, SMTI, Form 4, Insider Transaction, Tax Withholding, Executive Compensation